Hypha Labs Reports $521K Net Loss for Quarter, Shifts Focus to Bioreactor Development

Hypha Labs, Inc. reported its financial results for the three and six months ended March 31, 2026, revealing a net loss of $521,114 for the quarter and $1,042,752 for the half-year. This marks a decrease in net loss compared to the same periods in 2025, where the losses were $641,822 and $1,981,463, respectively. The company did not generate any revenue during these periods, maintaining a focus on operational restructuring and the development of new products. Operating expenses for the quarter totaled $420,393, down from $669,162 in the prior year, primarily due to a significant reduction in professional fees, which fell by 47% to $306,004.

The company's financial position has seen substantial changes since the previous fiscal period. As of March 31, 2026, Hypha Labs reported total assets of $159,819, a significant decline from $409,218 as of September 30, 2025. Current liabilities increased to $1,434,740 from $1,118,955, driven by higher accounts payable and accrued expenses. The company's stockholders' deficit also widened to $3,116,203, compared to $2,436,769 in the prior period, reflecting ongoing financial challenges.

Strategically, Hypha Labs has shifted its focus from cannabis testing to the development of the Hypha Micropearl bioreactor, a home appliance designed to produce nutritionally beneficial mushrooms. This transition follows the sale of its subsidiary, Digipath Labs, in February 2024. The company aims to complete the design and testing of the bioreactor over the next nine months, with plans to market the product by late 2026, contingent on successful development and funding.

Operationally, Hypha Labs has not reported any customer counts or user statistics, as it is in the early stages of launching its new product line. The company has increased its employee headcount, reflecting its commitment to developing the bioreactor technology. However, it faces significant liquidity challenges, with only $82,200 in cash on hand and negative working capital of $1,338,365. The company is actively seeking additional capital through equity or debt financing to support its operations and product development.

Looking ahead, Hypha Labs acknowledges substantial doubt about its ability to continue as a going concern, given its accumulated losses and current financial position. The company plans to raise funds to support the development and initial launch of the Hypha Micropearl bioreactor, but there is no assurance that it will be successful in securing the necessary financing. The management has indicated that it will continue to evaluate potential acquisition targets to enhance its market position, although the success of these initiatives remains uncertain.